ENTYVIO®
ENTYVIO® (Vedolizumab) is an anti-inflammatory drug used to treat Inflammatory Bowel Diseases.
ENTYVIO® is manufactured by Takeda.
Administration and Dosage:
Administration of ENTYVIO® follows an induction regimen of 3 intravenous infusions at 0, 2, and 6 weeks followed by a maintenance infusion, once every 8 weeks.
Common Side Effects:
The more common side effects of ENTYVIO® include infusion-related and serious allergic reactions, infections, Progressive Multifocal Leukoencephalopathy (PML), and liver problems.
More information:
Please read the full Prescribing Information and Medication Guide for ENTYVIO® and discuss any questions you have with your doctor.
Indication:
ENTYVIO® is indicated to treat:
Crohn’s Disease
Ulcerative Colitis
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Check our Privacy Practice